Clinical Trials Browser

Withdrawn × Ovarian Neoplasms × dostarlimab × Clear all

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Phase 3 Withdrawn

Ovarian Neoplasms